The U.S. has risen to become a leader in the global medtech industry, but this competitive edge is being threatened by the nation's corporate tax framework, writes B. Braun Medical Chairman and CEO Caroll Neubauer. "As Congress considers reforming the tax code to make U.S. business more competitive, repealing the medical device excise tax that went into effect in January is a critical first step to protecting jobs and ensuring a level playing field for ... the U.S. in the global economy," he writes.

Related Summaries